Fecal microbiota transplant as a potential treatment for Parkinson's disease – A case series
Arik Segal,Yair Zlotnik,Keren Moyal-Atias,Ran Abuhasira,Gal Ifergane
DOI: https://doi.org/10.1016/j.clineuro.2021.106791
IF: 1.885
2021-08-01
Clinical Neurology and Neurosurgery
Abstract:Fecal microbiota transplant (FMT) was safe in 6 Parkinson's Disease patients.FMT resulted in improvement in Parkinson's Disease motor symptoms at 6 months.FMT resulted in improvement in non-motor symptoms, including constipation.We aimed to determine whether Fecal microbiota transplant (FMT) is safe and possibly efficacious in treating constipation, motor, and non-motor symptoms in Parkinson's disease (PD) patients.Patients with PD, constipation and indication for screening colonoscopy were treated with FMT. The study was conducted from December 2017 to November 2019, and clinical outcomes assessing motor, non-motor and constipation symptoms were compared at baseline (week 0) and at 2, 4, 8, 12, 16, 20, and 24 weeks after the FMT.Six patients (3 men, age range 47-73, median age 52) were treated with FMT. Four weeks following the FMT, motor, non-motor and constipation scores were improved in 5 of 6 patients. At week 24, compared to before the FMT, the changes in motor scores ranged from -13 to 7 points, in non-motor scores from -2 to -45 points, and in constipation scores from -12 to 1 point. One patient had a serious adverse event requiring admission for observation only, and no adverse events were observed in all other patients.In this preliminary uncontrolled case series of 6 PD patients, a treatment with donor FMT infused via colonoscopy, was safe and resulted in improvement of PD motor and non-motor symptoms, including constipation, at 6 months. Further research is needed to assess longer-term maintenance of efficacy and safety, including in large scale randomized controlled trials.ClinicalTrials.gov – NCT03876327
surgery,clinical neurology